CVS Coverage Restoration for Zepbound and Foundayo: What It Means for GLP-1 Drug Costs and Patient Access
CVS has restored coverage for Eli Lilly's Zepbound and added the new oral GLP-1 pill Foundayo to its formulary, marking a significant shift in how patients can access tirzepatide-based obesity treatments. This change directly affects out-of-pocket costs, prior authorization requirements, and the overall landscape of GLP-1 affordability for millions of CVS Caremark plan members.
What CVS Actually Changed — and Why It Matters
Earlier, CVS Caremark had removed Zepbound from preferred coverage tiers on many of its formularies, effectively forcing patients to pay significantly higher out-of-pocket costs or switch to competing drugs. That decision created real financial hardship for people who were already managing complex obesity treatment plans. The restoration of Zepbound's coverage — alongside the newly approved oral option Foundayo — represents a meaningful reversal.
Foundayo is notable because it is an oral tirzepatide pill, offering patients who struggle with injectable medications an alternative delivery method. For PBMs like CVS Caremark, adding an oral GLP-1 option signals confidence that this drug class is here to stay as a covered benefit — not a discretionary one.
What Is Foundayo?
Foundayo is Eli Lilly's oral formulation of tirzepatide, the same active ingredient in Zepbound and Mounjaro. As a pill rather than a weekly injection, it lowers one of the most common barriers to GLP-1 adoption: needle aversion. Early clinical data suggests it can deliver meaningful weight loss outcomes, though injectable forms may still offer higher bioavailability for some patients.
What Is Zepbound?
Zepbound is Eli Lilly's FDA-approved injectable tirzepatide medication specifically indicated for chronic weight management. It works as a dual GIP and GLP-1 receptor agonist, a mechanism that distinguishes it from semaglutide-based drugs like Wegovy. Clinical trials showed participants losing up to 20.9% of their body weight over 72 weeks, according to results published in the New England Journal of Medicine.
How This Affects GLP-1 Drug Costs for Patients
The practical cost impact of CVS restoring Zepbound coverage depends heavily on your specific plan. However, the general principle holds: when a drug moves from non-preferred or excluded status back to preferred coverage, patients typically pay lower copays or coinsurance and face fewer prior authorization hurdles.
Before this change, some CVS Caremark plan members were effectively paying full list price — which for Zepbound runs approximately $1,059.87 per month for the standard 2.5 mg starting dose. That figure puts it squarely out of reach for most Americans without meaningful insurance support.
Covered vs. Non-Covered: The Real Cost Difference
When a GLP-1 drug like Zepbound is covered by a commercial insurance plan through CVS Caremark, patient out-of-pocket costs can drop dramatically. Covered plan members with standard commercial insurance may pay as little as $25 per month with Eli Lilly's savings card stacked on top of insurance benefits. Without coverage, that same medication could cost over $12,000 annually at list price.
To understand exactly what you might pay under your specific plan, you can use our GLP-1 cost calculator to estimate your real out-of-pocket expenses based on your insurance tier and drug selection.
Will Everyone on CVS Caremark Plans Benefit?
Not automatically. CVS Caremark administers benefits for thousands of employer plans and government programs, and each plan has its own formulary design. Some self-funded employer plans opt out of standard formulary updates. Patients should call the member services number on their insurance card or log in to their CVS Caremark portal to confirm whether Zepbound is now covered under their specific plan.
The Broader GLP-1 Coverage Landscape in 2025
The CVS decision doesn't happen in a vacuum. It reflects a wider reckoning in the insurance industry about how to handle GLP-1 drugs for obesity. For years, commercial insurers treated these medications differently than drugs for diabetes — often covering semaglutide under the Ozempic brand for type 2 diabetes while excluding Wegovy or Zepbound for weight loss despite near-identical mechanisms.
That inconsistency has faced increasing scrutiny from employers, patient advocates, and policymakers alike. Medicare Part D plans, for example, were previously prohibited from covering GLP-1 drugs for obesity under the Social Security Act — though that restriction has been the subject of ongoing legislative and regulatory debate. You can review CMS guidance on Medicare drug coverage policies at cms.gov/medicare/coverage.
Commercial Coverage Is Expanding — But Slowly
A 2024 KFF analysis found that roughly 43% of large employer plans covered at least one GLP-1 drug for obesity, up from just 25% in 2021. That trajectory suggests that moves like CVS's coverage restoration are more likely to become the norm than the exception as employers weigh the long-term cost savings of treating obesity against the immediate drug spend.
The Role of PBMs in Setting Your Drug Costs
Pharmacy Benefit Managers like CVS Caremark sit between drug manufacturers and patients. They negotiate rebates, set formulary tiers, and ultimately determine what patients pay at the pharmacy counter. When CVS negotiates preferred placement for Zepbound, Eli Lilly likely provides rebates that reduce the net cost to plans — which is why manufacturer-PBM negotiations directly shape your monthly costs even though most patients never see them.
What Foundayo's Addition Signals for Oral GLP-1 Pricing
Adding Foundayo to CVS's formulary is particularly interesting from a cost trajectory standpoint. Oral GLP-1 drugs have generally been priced comparably to their injectable counterparts, but as competition increases between oral and injectable forms, pricing pressure could eventually benefit consumers. Novo Nordisk's oral semaglutide (Rybelsus) is already on the market for diabetes management, and oral obesity-specific options are expected to intensify competition.
For patients who have been waiting for a non-injectable option, Foundayo's inclusion in a major PBM formulary is a meaningful access milestone. It also suggests CVS is betting on patient preference for convenience driving adherence — a factor that insurers care deeply about when evaluating cost-effectiveness.
Oral vs. Injectable GLP-1 Drugs: Cost Considerations
At launch, oral GLP-1 drugs have not historically been cheaper than injectables on a per-dose basis. However, they may reduce costs associated with needles, sharps disposal, and in some cases, medical visits for injection training. Patients should compare total cost of therapy — not just the drug price — when evaluating options. Our GLP-1 drug cost comparison tool can help you run those numbers side by side.
What You Should Do Now If You're a CVS Caremark Member
If you are currently taking Zepbound or considering starting it, here are the practical steps to take in light of this coverage change:
- Verify your formulary status: Log in to your CVS Caremark account or call the number on your insurance card to confirm Zepbound is on your plan's preferred tier.
- Ask about prior authorization: Even with formulary coverage, many plans require prior authorization for GLP-1 drugs. Your prescriber's office can submit this on your behalf.
- Check for Eli Lilly savings programs: Lilly offers a savings card for commercially insured patients that can reduce monthly costs substantially. Eligibility requirements apply.
- Compare Foundayo vs. Zepbound costs: If you're open to an oral option, ask your pharmacist or prescriber whether your plan covers Foundayo at a more favorable tier than the injectable form.
- Appeal if denied: If your plan still denies coverage, you have the right to appeal. Documentation of medical necessity from your physician is the most important tool in that process. CMS provides appeals guidance for Medicare-covered patients at cms.gov/medicare/appeals-and-grievances.
Frequently Asked Questions
Does the CVS coverage restoration mean Zepbound is now covered by all CVS Caremark plans?
No. CVS Caremark manages formularies for thousands of different employer and government plans. The restoration means Zepbound is being added back to CVS's standard commercial formulary templates, but individual employer plans may still exclude it if they have opted out of standard coverage. Always verify your specific plan's formulary directly through your CVS Caremark member portal or customer service line.
How much will I actually pay for Zepbound with CVS Caremark coverage?
Your exact cost depends on your plan's tier structure, deductible status, and whether you've met your out-of-pocket maximum for the year. Preferred-tier specialty drugs on commercial plans commonly carry copays ranging from $50 to $150 per month after deductibles are met — though some plans charge coinsurance percentages instead. Eli Lilly's savings card may reduce this further for eligible commercially insured patients. Use our GLP-1 cost calculator to estimate your personalized out-of-pocket expense.
Is Foundayo covered by Medicare or Medicaid?
Medicare Part D coverage for GLP-1 drugs used specifically for obesity remains a complex and evolving area. As of now, Medicare has been prohibited from covering weight-loss drugs under most Part D plans, though legislative proposals to change this have gained momentum. Medicaid coverage varies by state. Patients on government insurance programs should consult their plan directly and monitor ongoing regulatory developments from CMS.
What is the list price of Foundayo compared to Zepbound?
Eli Lilly has not released Foundayo's final list price at the time of this writing, as the drug received recent approval. Historically, oral GLP-1 formulations have been priced comparably to injectable versions, but manufacturer pricing decisions and PBM negotiations will ultimately determine what patients pay. Check back as pricing details become publicly available.